Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-25

Clinical Trial Update: Study of Poziotinib in Japanese Patients With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Poziotinib in Japanese patients with non-small cell lung cancer was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Poziotinib (poziotinib)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: NSCLC | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-25